leisure time -WSS

leisure time

author：entertainment 2025-09-10 02:24:02 - browse：86251

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： World's first CRISPR

Wikipedia

WSS

Study says nonprofit hospitals fall short in charity care spending

Anthos stroke drug appears safer than common blood thinner

Hospitals look to new technology to keep health care workers safe

Study says nonprofit hospitals fall short in charity care spending

Readout Newsletter: Merck, Vertex, and Viking updates

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

focus

leisure time

leisure time

At least 13 dead in Texas as scorching temps continue

Eliminate the waiting period for sterilization covered by Medicaid

Affirmative action in medical school literally saved lives

Readout Newsletter: Merck, Vertex, and Viking updates

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: mifepristone case, GLP

Jerome Adams on the need for new antivirals for Covid

CRISPR pioneers react to Casgevy, first gene

At least 13 dead in Texas as scorching temps continue

Abortion pill case raises question: who can sue the FDA?

Wikipedia

Washington mulls new rules to avert another Change Healthcare

FDA's naming rule on biosimilars has undermined competition

CRISPR pioneers react to Casgevy, first gene

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Primary care physicians play key roles in Alzheimer's management

Why the world’s most expensive drug might be worth the price

Wikipedia

knowledge

entertainment

entertainment